Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Barrans, S. Crouch, Alex Smith, K. Turner, R. Owen, R. Patmore, E. Roman, A. Jack (2010)
Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 20
Wyndham Wilson, Sin-Ho Jung, Pierluigi Porcu, David Hurd, Jeffrey Johnson, S. Martin, M. Czuczman, Raymond Lai, Jonathan Said, Amy Chadburn, Dan Jones, K. Dunleavy, George Canellos, A. Zelenetz, B. Cheson, E. Hsi (2012)
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtypeHaematologica, 97
(2011)
Myc+ aggressive B-cell lymphomas: novel therapy of untreated Burkitt Lymphoma (BL) andMYC+diffuse largeB-cell lymphoma (DLBCL) with DA-EPOCH-R
(2014)
PreliminaryReport of aMulticenter ProspectivePhase II Study ofDA-EPOCHRinMYC-RearrangedAggressiveB-CellLymphoma
Y. Oki, M. Noorani, P. Lin, R. Davis, S. Neelapu, Long Ma, M. Ahmed, Maria Rodriguez, F. Hagemeister, N. Fowler, Michael Wang, M. Fanale, L. Nastoupil, F. Samaniego, H. Lee, B. Dabaja, C. Pinnix, L. Medeiros, Y. Nieto, I. Khouri, L. Kwak, F. Turturro, J. Romaguera, L. Fayad, J. Westin (2014)
Double hit lymphoma: the MD Anderson Cancer Center clinical experienceBritish Journal of Haematology, 166
B. Coiffier, C. Thieblemont, E. Neste, G. Lepeu, I. Plantier, S. Castaigne, S. Lefort, G. Marit, M. Macro, C. Sebban, K. Belhadj, D. Bordessoule, C. Fermé, H. Tilly (2010)
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.Blood, 116 12
(2014)
Doublehit lymphoma : theMD AndersonCancerCenterclinicalexperience
D Jong, A Rosenwald, M Chhanabhai (2007)
Lunenburg Lymphoma Biomarker Consortium. Immunohistochemical prognostic markers in diffuse large B‑cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications – a study from the Lunenburg Lymphoma Biomarker ConsortiumJ Clin Oncol, 25
Zheng Zhou, L. Sehn, A. Rademaker, L. Gordon, A. LaCasce, Allison Crosby‐Thompson, A. Vanderplas, A. Zelenetz, G. Abel, M. Rodriguez, A. Nademanee, M. Kaminski, M. Czuczman, M. Millenson, J. Niland, R. Gascoyne, J. Connors, J. Friedberg, J. Winter (2014)
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.Blood, 123 6
K. Dunleavy, S. Pittaluga, M. Shovlin, S. Steinberg, D. Cole, C. Grant, B. Widemann, L. Staudt, E. Jaffe, R. Little, W. Wilson (2013)
Low-intensity therapy in adults with Burkitt's lymphoma.The New England journal of medicine, 369 20
C. Récher, B. Coiffier, C. Haioun, T. Molina, C. Fermé, O. Casasnovas, C. Thieblemont, A. Bosly, G. Laurent, F. Morschhauser, H. Ghesquières, F. Jardin, S. Bologna, C. Fruchart, B. Corront, J. Gabarre, C. Bonnet, M. Janvier, D. Canioni, J. Jais, G. Salles, H. Tilly (2011)
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trialThe Lancet, 378
(2010)
RearrangementofMYC is associated with poor prognosis in patients with diffuse largeB-cell lymphomatreatedintheeraof rituximab
A Rosenwald, G Wright, WC Chan (2002)
Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphomaN Engl J Med, 346
M. Roschewski, L. Staudt, W. Wilson (2014)
Diffuse large B-cell lymphoma—treatment approaches in the molecular eraNature Reviews Clinical Oncology, 11
Ash Alizadeh, M. Eisen, R. Davis, Chishieva Ma, I. Lossos, A. Rosenwald, Jennifer Boldrick, H. Sabet, T. Tran, Xin Yu, J. Powell, Liming Yang, G. Marti, T. Moore, J. Hudson, Li-Sheng Lu, D. Lewis, R. Tibshirani, G. Sherlock, W. Chan, T. Greiner, D. Weisenburger, J. Armitage, R. Warnke, R. Levy, W. Wilson, M. Grever, J. Byrd, D. Botstein, Pat Brown, L. Staudt (2000)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 403
K. Dunleavy, M. Fanale, A. LaCasce, A. Noy, P. Caimi, S. Parekh, J. Hayslip, D. Jagadeesh, R. Lord, M. Lechowicz, R. Gaur, A. Lucas, L. Staudt, S. Steinberg, B. Kahl, J. Friedberg, R. Little, N. Bartlett, W. Wilson (2014)
Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell LymphomaBlood, 124
G. Lai, Yi-nan Chen, L. Mickley, A. Fojo, S. Bates (1991)
P‐glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell linesInternational Journal of Cancer, 49
N. Johnson, G. Slack, K. Savage, J. Connors, S. Ben-Neriah, S. Rogic, D. Scott, K. Tan, C. Steidl, L. Sehn, W. Chan, J. Iqbal, Paul Meyer, G. Lenz, George Wright, L. Rimsza, C. Valentino, P. Brunhoeber, T. Grogan, R. Braziel, J. Cook, R. Tubbs, D. Weisenburger, E. Campo, A. Rosenwald, G. Ott, J. Delabie, C. Holcroft, E. Jaffe, L. Staudt, R. Gascoyne (2012)
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 28
C. Gisselbrecht, B. Glass, N. Mounier, Devinder Gill, D. Linch, M. Trněný, A. Bosly, N. Ketterer, O. Shpilberg, H. Hagberg, D. Ma, J. Brière, C. Moskowitz, N. Schmitz (2010)
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 27
N. Schmitz, M. Nickelsen, M. Ziepert, M. Haenel, P. Borchmann, C. Schmidt, A. Viardot, M. Bentz, N. Peter, G. Ehninger, G. Doelken, C. Ruebe, L. Truemper, A. Rosenwald, M. Pfreundschuh, M. Loeffler, B. Glass (2012)
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).The Lancet. Oncology, 13 12
P. Stiff, J. Unger, J. Cook, L. Constine, S. Couban, D. Stewart, T. Shea, P. Porcu, J. Winter, B. Kahl, T. Miller, R. Tubbs, D. Marcellus, J. Friedberg, K. Barton, G. Mills, M. LeBlanc, L. Rimsza, S. Forman, R. Fisher (2013)
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.The New England journal of medicine, 369 18
Paul Meyer, K. Fu, T. Greiner, Lynette Smith, J. Delabie, R. Gascoyne, G. Ott, A. Rosenwald, R. Braziel, E. Campo, J. Vose, G. Lenz, L. Staudt, W. Chan, D. Weisenburger (2011)
Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 2
K. Dunleavy, S. Pittaluga, L. Maeda, R. Advani, Clara Chen, Julieanne Hessler, S. Steinberg, C. Grant, George Wright, Gaurav Varma, L. Staudt, E. Jaffe, W. Wilson (2013)
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.The New England journal of medicine, 368 15
T. Green, K. Young, C. Visco, Z. Xu-Monette, A. Orazi, R. Go, O. Nielsen, O. Gadeberg, T. Mourits‐Andersen, Mikael Frederiksen, L. Pedersen, M. Møller (2012)
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 28
A. Petrich, M. Gandhi, B. Jovanovic, J. Castillo, S. Rajguru, David Yang, K. Shah, Jeremy Whyman, F. Lansigan, F. Hernandez-Ilizaliturri, L. Lee, S. Barta, Shruthi Melinamani, R. Karmali, Camille Adeimy, Scott Smith, Neil Dalal, C. Nabhan, D. Peace, J. Vose, A. Evens, N. Shah, T. Fenske, A. Zelenetz, D. Landsburg, C. Howlett, A. Mato, M. Jaglal, J. Chavez, Judy Tsai, N. Reddy, Shaoying Li, C. Handler, C. Flowers, Jonathon Cohen, Jonathon Cohen, K. Blum, K. Song, H. Sun, O. Press, R. Cassaday, J. Jaso, L. Medeiros, A. Sohani, J. Abramson (2014)
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.Blood, 124 15
V. Ribrag, S. Koscielny, J. Bosq, T. Leguay, O. Casasnovas, L. Fornecker, C. Récher, H. Ghesquières, F. Morschhauser, S. Girault, S. Gouill, M. Ojeda-Uribe, C. Mariette, J. Cornillon, G. Cartron, V. Vergé, C. Chassagne‐Clément, H. Dombret, B. Coiffier, T. Lamy, H. Tilly, G. Salles (2016)
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trialThe Lancet, 387
(2014)
WilsonWHDiffuse large B - cell lymphoma - treatmentapproachesinthemolecularera
D. Hoelzer, J. Walewski, H. Döhner, A. Viardot, W. Hiddemann, K. Spiekermann, H. Serve, U. Dührsen, A. Hüttmann, E. Thiel, J. Dengler, M. Kneba, M. Schaich, I. Schmidt-Wolf, J. Beck, B. Hertenstein, A. Reichle, K. Domanska-Czyz, R. Fietkau, H. Horst, H. Rieder, S. Schwartz, T. Burmeister, N. Gökbuget (2014)
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial.Blood, 124 26
G Lenz, LM Staudt (2010)
Aggressive lymphomasN Engl J Med, 362
M. Maurer, H. Ghesquières, J. Jais, T. Witzig, C. Haioun, C. Thompson, R. Delarue, I. Micallef, F. Peyrade, W. Macon, Thierry Molina, N. Ketterer, S. Syrbu, O. Fitoussi, Paul Kurtin, C. Allmer, E. Nicolas‐Virelizier, S. Slager, T. Habermann, B. Link, G. Salles, H. Tilly, J. Cerhan (2014)
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 10
A. Rosenwald, George Wright, W. Chan, J. Connors, E. Campo, R. Fisher, R. Gascoyne, H. Muller-Hermelink, E. Smeland, J. Giltnane, E. Hurt, Hong Zhao, Lauren Averett, Liming Yang, W. Wilson, E. Jaffe, R. Simon, R. Klausner, J. Powell, P. Duffey, D. Longo, T. Greiner, D. Weisenburger, W. Sanger, B. Dave, J. Lynch, J. Vose, J. Armitage, E. Montserrat, A. López-Guillermo, T. Grogan, T. Miller, M. LeBlanc, G. Ott, S. Kvaløy, J. Delabie, H. Holte, P. Krajči, T. Stokke, L. Staudt (2002)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.The New England journal of medicine, 346 25
(2000)
Distinct types of diffuselargeB-cell lymphomaidentifiedbygeneexpression profiling.Nature
W. Wilson, M. Grossbard, S. Pittaluga, D. Cole, D. Pearson, Nicole Drbohlav, S. Steinberg, R. Little, J. Janik, M. Gutiérrez, M. Raffeld, L. Staudt, B. Cheson, D. Longo, N. Harris, E. Jaffe, B. Chabner, R. Wittes, F. Balis (2002)
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.Blood, 99 8
C. Howlett, S. Snedecor, D. Landsburg, J. Svoboda, E. Chong, S. Schuster, S. Nasta, T. Feldman, A. Rago, Kristy Walsh, Scott Weber, A. Goy, A. Mato (2015)
Front‐line, dose‐escalated immunochemotherapy is associated with a significant progression‐free survival advantage in patients with double‐hit lymphomas: a systematic review and meta‐analysisBritish Journal of Haematology, 170
(2014)
Improvedoutcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
(2013)
Autologoustransplantation as consolidation for aggressivenon - Hodgkin ’ s lymphoma
M. Hertzberg, M. Gandhi, B. Butcher, Ruth Columbus, J. Taper, J. Trotman, D. Gill, Shir-Jing Ho, Kelth Fay, G. Cull, A. Grigg, G. Chong, I. Lewis, S. Milliken, William Renwick, U. Hahn, R. Filshie, A. Watson, G. Kannourakis, M. Wolf, A. Wirth, P. Warburton, S. Larsen, J. Seymour, R. Hicks (2015)
Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after FourBlood, 126
M. Gutiérrez, B. Chabner, D. Pearson, S. Steinberg, E. Jaffe, B. Cheson, A. Fojo, W. Wilson (2000)
Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 21
C. Hans, D. Weisenburger, T. Greiner, R. Gascoyne, J. Delabie, G. Ott, H. Müller-hermelink, E. Campo, R. Braziel, E. Jaffe, Zenggang Pan, Pedro Farinha, Lynette Smith, B. Falini, A. Banham, A. Rosenwald, L. Staudt, J. Connors, J. Armitage, W. Chan (2004)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.Blood, 103 1
K. Savage, N. Johnson, S. Ben-Neriah, J. Connors, L. Sehn, Pedro Farinha, D. Horsman, R. Gascoyne (2009)
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.Blood, 114 17
B. Cusack, S. Young, J. Driskell, R. Olson (2004)
Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbitCancer Chemotherapy and Pharmacology, 32
G Lenz, G Wright, SS Dave (2008)
Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomasN Engl J Med, 359
(2000)
Distinct types of diffuselargeB - cell lymphomaidentifiedbygeneexpression profiling
H. Gharwan, Catherine Lai, C. Grant, K. Dunleavy, S. Steinberg, M. Shovlin, T. Fojo, W. Wilson (2016)
Female fertility following dose-adjusted EPOCH-R chemotherapy in primary mediastinal B-cell lymphomasLeukemia & Lymphoma, 57
D. Jong, A. Rosenwald, M. Chhanabhai, P. Gaulard, W. Klapper, Abigail Lee, B. Sander, C. Thorns, E. Campo, T. Molina, A. Norton, A. Hagenbeek, S. Horning, A. Lister, J. Raemaekers, R. Gascoyne, G. Salles, E. Weller (2007)
Retracted: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium)Journal of Clinical Pathology, 62
Shimin Hu, Z. Xu-Monette, A. Tzankov, T. Green, Lin Wu, A. Balasubramanyam, Wei-min Liu, C. Visco, Yong Li, R. Miranda, S. Montes-Moreno, K. Dybkaer, A. Chiu, A. Orazi, Y. Zu, G. Bhagat, K. Richards, E. Hsi, W. Choi, Xiaoying Zhao, J. Krieken, Qin Huang, J. Huh, W. Ai, M. Ponzoni, A. Ferreri, F. Zhou, G. Slack, R. Gascoyne, M. Tu, D. Variakojis, Weina Chen, R. Go, M. Piris, M. Møller, L. Medeiros, K. Young (2013)
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.Blood, 121 20
(2011)
Immunohistochemical methodsforpredictingcelloforiginandsurvival inpatients withdiffuse largeB-cell lymphoma treatedwith rituximab
MS Hertzberg, MK Gandhi, B Butcher (2015)
Early treatment intensification with R‑ICE chemotherapy followed by autologous stem cell transplantation (ASCT) using Zevalin-BEAM for patients with poor risk dffuse large B‑cell lymphoma (DLBCL) as identified by interim PET/CT scan performed after four cycles of R‑CHOP-14: a multicenter phase II study of the australasian leukaemia lymphoma study group (ALLG)Blood, 126
(2000)
Role of adoxorubicin-containingregimeninrelapsedandresistant lymphomas: an 8-year follow-upof study of EPOCH
G. Lenz, George Wright, S. Dave, Wenming Xiao, J. Powell, Huaqing Zhao, Wei Xu, Bruce Tan, N. Goldschmidt, J. Iqbal, J. Vose, M. Bast, K. Fu, D. Weisenburger, T. Greiner, J. Armitage, A. Kyle, L. May, R. Gascoyne, J. Connors, G. Trøen, H. Holte, S. Kvaløy, D. Dierickx, G. Verhoef, J. Delabie, E. Smeland, P. Jares, A. Martínez, A. López-Guillermo, E. Montserrat, E. Campo, R. Braziel, T. Miller, L. Rimsza, J. Cook, B. Pohlman, J. Sweetenham, R. Tubbs, R. Fisher, E. Hartmann, A. Rosenwald, G. Ott, G. Ott, H. Müller-Hermelink, D. Wrench, T. Lister, E. Jaffe, W. Wilson, W. Chan, L. Staudt (2008)
Stromal gene signatures in large-B-cell lymphomas.The New England journal of medicine, 359 22
N. Purroy, J. Bergua, L. Gallur, J. Prieto, L. Lopez, J. Sancho, J. García-Marco, J. Castellví, S. Montes-Moreno, A. Batlle, S. Villambrosia, F. Carnicero, L. Ferrando-Lamana, M. Piris, Andrés López (2015)
Long‐term follow‐up of dose‐adjusted EPOCH plus rituximab (DA‐EPOCH‐R) in untreated patients with poor prognosis large B‐cell lymphoma. A phase II study conducted by the Spanish PETHEMA GroupBritish Journal of Haematology, 169
L. Pasqualucci (2013)
The genetic basis of diffuse large B-cell lymphomaCurrent Opinion in Hematology, 20
(2011)
Intensifiedchemother - apy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B - cell lymphoma ( LNH 032 B ) : an open - label randomised phase 3 trial
J. Friedberg (2012)
Double-hit diffuse large B-cell lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 28
M. Dreyling, Georg Lenz, Gilles Salles, J. Cerhan (2020)
Aggressive LymphomasLiječnički vjesnik
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma with an annual incidence of 7–8 cases per 100,000 per year. With standard induction therapy comprising rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R/CHOP), 40% of all patients get cured. Patients relapsing or being refractory to R/CHOP have a poor prognosis with a 10 % cure rate. On the other hand, the prognosis for patients with an event-free survival of 24 months is excellent. Despite the possibility of identifying patients at high risk for R/CHOP failure at the time of diagnosis, to date, an adequate risk-adapted induction has not been established. Dose-adjusted application of rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH-R) is a pharmacodynamic approach to improve R/CHOP by the addition of etoposide, prolonged exposure to chemotherapy agents (continuous infusion of etoposide, vincristine, and doxorubicin over 96 h) and dose adjustment based on the absolute neutrophil count nadir. DA-EPOCH-R has shown promising results in retrospective analyses of various high-risk DLBCL cases. The following article reviews various approaches to define and to treat patients with high-risk DLBCL with a focus on treatment with DA-EPOCH-R.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Oct 28, 2016
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.